Meso Scale Discovery Assay: The Future of Bioanalytical Testing?

Meso Scale Discovery assay can detect and measure analytes in complex biological samples. Meso Scale Discovery multiplex technology employs electrochemiluminescence detection and multi-array technology to provide singleplex and multiplex assay formats. The combination of patterned array and electrochemiluminescence detection delivers highly dense information and rapid analysis through miniaturization and parallel processing of study samples. A Bioanalytical laboratory s can choose from a wide range of assay kits and reagents. MSD labs have access to assays such as MSD PK assay, MSD cytokines multiplex assay, MSD ADA assay, and MSD cell-based assay. Besides, the MSD assay protocol is streamlined to accelerate drug development studies. 

Meso Scale Discovery assay

MSD offers a unique assay platform to quantify analytes in biological samples. With over 400 kits, including PK mesoscale assay, ADA MSD assay, and mesoscale cytokine multiplex assays, researchers can precisely measure phosphoproteins, biomarkers, and cytokines in complex study matrices. In crucial studies, such as PK testing, Meso Scale pharmacokinetic assay delivers high-quality data in less time, with low cost and minimal effort. Such characteristics have made MSD technology a leading player in the pharmaceutical industry, biotech companies, clinical research organizations, and government and academic institutions. 

Electrochemiluminescence detection technology used in MSD works on Sulfo-tag labels. When stimulated, these labels emit a light signal, which correlates to the amount of analyte present in the sample.

Electrochemiluminescence detection has several advantages. 

  • Minimal background signal
  • Close proximity and hence enabling non-wash assays
  • Stable and nonradioactive labels offering flexibility
  • No color quenching issues
  • Multiple excitation cycles resulting in signal amplification and improved sensitivity
  • Flexible surface coating
  • Carbon electrode providing 10X binding capacities
  • Custom patterns and surface coatings

The multi-array technology is the hallmark of MSD technology. Each well has up to ten spots, exponentially increasing the detection capacities of MSD assays. MSD offers ultra-low detection limits, a broader dynamic range, and uses minimal study samples. Such features enable researchers to measure native levels of analysis in disease and normal study samples without multiple assay dilutions. 

Clinical samples are inherently challenging. Evaluating these difficult study samples using traditional immunoassays such as ELISA is demanding. Besides widely ranging analyte concentrations, complex study material and limited biological samples can make these challenges even more daunting. MSD assays can easily overcome all these challenges. Besides, they are available in validated packages and software supported by GLP-compliance and 21 CFR Part 11, making them an ideal choice for highly regulated workflows. 

Most toxicological studies involve assessing changes through a combination of potential biomarkers and histochemical endpoints. The best biomarker assay should be specific to a tissue type or organ. Toxicologists require systems that can provide high sensitivity and a broader dynamic range with consistent performance. MSD assays offer all these features plus multiplexing capacities to save biological samples and time. 

MSD offers custom assay development at each stage of the R&D process. They provide a distinct combination to meet all assay needs. When needed, they can work with specific references to deliver custom assay development along with a dedicated MSD assay protocol. Besides, they have a dedicated team of scientists to support clients both virtually and onsite. In conclusion, Meso Scale Discovery assays have the potential to change the future of bioanalytical testing. 

Leave comment

Your email address will not be published. Required fields are marked with *.